In addition, there was a significantly higher ratio of CD8+/CD45+ cells (14.1% ± 0.2% vs. 7.6% ± 0.7%) in the control group than in the treatment group before tumor rechallenge; however, this difference was not observed after tumor rechallenge. The gene discussed is CD8A; the disease is neoplasm.